BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 26935606)

  • 1. Functional analysis of the TMPRSS2:ERG fusion gene in cisplatin‑induced cell death.
    Wu J; Chi L; Chen Z; Lu X; Xiao S; Zhang G; Luo J; Chen GM; Yang J
    Mol Med Rep; 2016 Apr; 13(4):3173-80. PubMed ID: 26935606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of the TMPRSS2:ERG gene fusion in prostate cancer.
    Wang Z; Wang Y; Zhang J; Hu Q; Zhi F; Zhang S; Mao D; Zhang Y; Liang H
    Mol Med Rep; 2017 Oct; 16(4):5450-5458. PubMed ID: 28849022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antineoplastic Effects of siRNA against TMPRSS2-ERG Junction Oncogene in Prostate Cancer.
    Urbinati G; Ali HM; Rousseau Q; Chapuis H; Desmaële D; Couvreur P; Massaad-Massade L
    PLoS One; 2015; 10(5):e0125277. PubMed ID: 25933120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of novel TMPRSS2:ERG mechanisms in prostate cancer metastasis: involvement of MMP9 and PLXNA2.
    Tian TV; Tomavo N; Huot L; Flourens A; Bonnelye E; Flajollet S; Hot D; Leroy X; de Launoit Y; Duterque-Coquillaud M
    Oncogene; 2014 Apr; 33(17):2204-14. PubMed ID: 23708657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer.
    Swanson TA; Krueger SA; Galoforo S; Thibodeau BJ; Martinez AA; Wilson GD; Marples B
    Prostate; 2011 Oct; 71(14):1548-58. PubMed ID: 21394739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of TMPRSS2-ERG mechanisms in prostate cancer invasiveness: Involvement of MMP-9 and plexin B1.
    Liu B; Gu X; Huang T; Luan Y; Ding X
    Oncol Rep; 2017 Jan; 37(1):201-208. PubMed ID: 28004109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abnormal expression of the ERG transcription factor in prostate cancer cells activates osteopontin.
    Flajollet S; Tian TV; Flourens A; Tomavo N; Villers A; Bonnelye E; Aubert S; Leroy X; Duterque-Coquillaud M
    Mol Cancer Res; 2011 Jul; 9(7):914-24. PubMed ID: 21669963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer.
    Thangapazham R; Saenz F; Katta S; Mohamed AA; Tan SH; Petrovics G; Srivastava S; Dobi A
    BMC Cancer; 2014 Jan; 14():16. PubMed ID: 24418414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer.
    Setlur SR; Mertz KD; Hoshida Y; Demichelis F; Lupien M; Perner S; Sboner A; Pawitan Y; Andrén O; Johnson LA; Tang J; Adami HO; Calza S; Chinnaiyan AM; Rhodes D; Tomlins S; Fall K; Mucci LA; Kantoff PW; Stampfer MJ; Andersson SO; Varenhorst E; Johansson JE; Brown M; Golub TR; Rubin MA
    J Natl Cancer Inst; 2008 Jun; 100(11):815-25. PubMed ID: 18505969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TMPRSS2-ERG fusion protein regulates insulin-like growth factor-1 receptor (IGF1R) gene expression in prostate cancer: involvement of transcription factor Sp1.
    Meisel Sharon S; Pozniak Y; Geiger T; Werner H
    Oncotarget; 2016 Aug; 7(32):51375-51392. PubMed ID: 27285981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models.
    Ateeq B; Vellaichamy A; Tomlins SA; Wang R; Cao Q; Lonigro RJ; Pienta KJ; Varambally S
    Prostate; 2012 Oct; 72(14):1542-9. PubMed ID: 22415461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The TMPRSS2-ERG Gene Fusion Blocks XRCC4-Mediated Nonhomologous End-Joining Repair and Radiosensitizes Prostate Cancer Cells to PARP Inhibition.
    Chatterjee P; Choudhary GS; Alswillah T; Xiong X; Heston WD; Magi-Galluzzi C; Zhang J; Klein EA; Almasan A
    Mol Cancer Ther; 2015 Aug; 14(8):1896-906. PubMed ID: 26026052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TMPRSS2-ERG Fusion Promotes Recruitment of Regulatory T cells and Tumor Growth in Prostate Cancer.
    Shan L; Ji T; Su X; Shao Q; Du T; Zhang S
    Am J Med Sci; 2018 Jul; 356(1):72-78. PubMed ID: 30049331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer].
    Dai MJ; Chen LL; Zheng YB; Chen W; Tao ZH; Weng ZL; Wu XL; Li CD; Chen ZG; Chen XD; Shi SB
    Zhonghua Yi Xue Za Zhi; 2008 Mar; 88(10):669-73. PubMed ID: 18642766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts.
    Wang J; Cai Y; Yu W; Ren C; Spencer DM; Ittmann M
    Cancer Res; 2008 Oct; 68(20):8516-24. PubMed ID: 18922926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer.
    Winnes M; Lissbrant E; Damber JE; Stenman G
    Oncol Rep; 2007 May; 17(5):1033-6. PubMed ID: 17390040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TMPRSS2-ERG fusion promotes prostate cancer metastases in bone.
    Deplus R; Delliaux C; Marchand N; Flourens A; Vanpouille N; Leroy X; de Launoit Y; Duterque-Coquillaud M
    Oncotarget; 2017 Feb; 8(7):11827-11840. PubMed ID: 28055969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
    Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
    Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of TMPRSS2-ERG gene fusion in negative regulation of PSMA expression.
    Yin L; Rao P; Elson P; Wang J; Ittmann M; Heston WD
    PLoS One; 2011; 6(6):e21319. PubMed ID: 21731703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis.
    Saramäki OR; Harjula AE; Martikainen PM; Vessella RL; Tammela TL; Visakorpi T
    Clin Cancer Res; 2008 Jun; 14(11):3395-400. PubMed ID: 18519769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.